Placebo News and Research

RSS

Extremely premature babies should not be given drug to prevent fatal fungal infection

In most circumstances, extremely premature babies should not be given a drug to prevent a potentially fatal fungal infection, according to findings by a Duke Medicine-led research team.

5 May 2014

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

New two-year data from the Phase 3 ADVANCE clinical trial for peginterferon beta-1a in adults with relapsing forms of multiple sclerosis (RMS) has been presented at the 66th American Academy of Neurology (AAN) annual meeting.

5 May 2014

High-dose steroid therapy following surgery do not improve bile drainage among infants

Among infants who underwent surgery to repair bile ducts that do not drain properly (biliary atresia), the administration of high-dose steroid therapy following surgery did not significantly improve bile drainage after 6 months, although a small clinical benefit could not be excluded, according to a study in the May 7 issue of JAMA, a theme issue on child health.

5 May 2014

High doses of steroids fail to improve outcomes in pediatric liver disease

A multi-center study concludes that treating infants with high doses of steroids fails to improve medical outcomes in the end-stage pediatric liver disease biliary atresia and leads to earlier onset of serious adverse events.

5 May 2014

Research provides definitive evidence of safety of Tdap immunization during pregnancy

A preliminary study finds that receipt of the tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis (Tdap) vaccine in the third trimester of pregnancy did not increase the risk of adverse events for the mother or infant, according to a study in the May 7 issue of JAMA, a theme issue on child health.

5 May 2014

Prenatal DHA supplementation does not improve cognitive outcomes in children

Although there are recommendations for pregnant women to increase their intake of the omega-3 fatty acid docosahexaenoic acid (DHA) to improve fetal brain development, a randomized trial finds that prenatal DHA supplementation did not result in improved cognitive, problem-solving or language abilities for children at four years of age, according to the study in the May 7 issue of JAMA, a theme issue on child health.

5 May 2014

Long-term use of drug combination reduces risk of recurrent urinary tract infection in children

Long-term use of a drug combination reduces the risk of recurrent urinary tract infection by up to 80 percent in children with the urinary condition vesicoureteral reflux compared to placebo, according to research funded by the National Institutes of Health.

5 May 2014

Daily multivitamin offers modest protection against cataracts

Long-term daily use of multivitamins could help to reduce the risk of cataracts, but has no effect on the risk of visually significant age-related macular degeneration, suggests research.

1 May 2014

Antipsychotic response faster than thought

Differences between antipsychotic and placebo treatment emerge within 4 weeks of starting therapy, an analysis of randomised, controlled trials shows.

1 May 2014

Teva announces positive results from pivotal Phase III study of hydrocodone bitartrate extended-release tablets

Teva Pharmaceutical Industries Ltd. today announced positive results from a pivotal Phase III study of hydrocodone bitartrate extended-release tablets designed with Teva's proprietary technology providing potential abuse-deterrent properties (CEP-33237).

30 Apr 2014

Purdue Pharma seeks FDA authorization to market once-daily hydrocodone bitartrate tablet

Purdue Pharma L.P. announced that it has filed a New Drug Application (NDA) with the U.S. Food & Drug Administration seeking authorization to market a once-daily, single-entity hydrocodone bitartrate tablet (HYD).

30 Apr 2014

Braeburn announces new clinical trial for Probuphine based on clear guidance from FDA

Braeburn Pharmaceuticals announced today the initiation of a new clinical trial for Probuphine® based on clear guidance from the U.S. Food and Drug Administration (FDA). The study, which was submitted for FDA review in mid-March, is expected to begin enrollment by mid-year and to be completed by the middle of 2015.

30 Apr 2014

Synergy reports positive top-line results from plecanatide phase 2b study in patients with IBS-C

Synergy Pharmaceuticals Inc. today announced positive top-line results from a phase 2b dose-ranging study assessing plecanatide's safety and efficacy in 424 patients with irritable bowel syndrome with constipation (IBS-C).

30 Apr 2014

Otsuka's Deltyba gets EC marketing authorization for MDR-TB treatment

Otsuka Pharmaceutical Co., Ltd. today announced that the European Commission has granted a marketing authorization for Deltyba (delamanid) for use as part of an appropriate combination regimen for pulmonary multidrug-resistant tuberculosis (MDR-TB) in adult patients when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability.

30 Apr 2014

Review: Stem cell therapy for chronic ischaemic heart disease

Stem cell therapies work as a complement to standard treatments, potentially cutting the number of deaths after a year, suggests evidence from the latest Cochrane review: Stem cell therapy for chronic ischaemic heart disease and congestive heart failure.

30 Apr 2014

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that it has submitted a study protocol to the U.S. Food and Drug Administration for its Phase II clinical trial of CF102 for the treatment of advanced liver cancer.

29 Apr 2014

The rising incidence of multi-drug resistant TB: an interview with Dr Myriam Haxaire-Theeuwes, Compound Development Team Leader, Janssen

MDR-TB is on the rise in a number of regions in the world, because progress towards targets for diagnosis and treatment of multidrug-resistant TB (MDR-TB) is far off-track.

29 Apr 2014

Civitas reports positive results from CVT-301 Phase 2b trial for treatment of Parkinson's disease

Civitas Therapeutics, Inc., a privately-held pharmaceutical company developing and commercializing transformative therapeutics using its proprietary ARCUSTM technology, today announced positive results from a Phase 2b clinical trial of CVT-301, an inhaled formulation of levodopa (L-dopa).

29 Apr 2014

Positive results from pivotal clinical trial of Trophos’ olesoxime in SMA patients to be presented at AAN 2014

Trophos and AFM-Telethon today announce that data from the pivotal clinical trial of Trophos’ lead product candidate olesoxime in spinal muscular atrophy (SMA) will be presented during the 66th American Academy of Neurology annual meeting to be held in Philadelphia, PA, USA, from April 26 to May 3 2014.

29 Apr 2014

Inflammation has ‘etiologic link’ with prostate cancer

Chronic inflammation of prostate tissue is strongly associated with subsequent development of prostate cancer, show results of a US observational study.

28 Apr 2014

Placebo News and Research

Extremely premature babies should not be given drug to prevent fatal fungal infection

New two-year data from Biogen Idec’s Phase 3 trial for peginterferon beta-1a presented at AAN annual meeting

High-dose steroid therapy following surgery do not improve bile drainage among infants

High doses of steroids fail to improve outcomes in pediatric liver disease

Research provides definitive evidence of safety of Tdap immunization during pregnancy

Prenatal DHA supplementation does not improve cognitive outcomes in children

Long-term use of drug combination reduces risk of recurrent urinary tract infection in children

Daily multivitamin offers modest protection against cataracts

Antipsychotic response faster than thought

Teva announces positive results from pivotal Phase III study of hydrocodone bitartrate extended-release tablets

Purdue Pharma seeks FDA authorization to market once-daily hydrocodone bitartrate tablet

Braeburn announces new clinical trial for Probuphine based on clear guidance from FDA

Synergy reports positive top-line results from plecanatide phase 2b study in patients with IBS-C

Otsuka's Deltyba gets EC marketing authorization for MDR-TB treatment

Review: Stem cell therapy for chronic ischaemic heart disease

Can-Fite BioPharma submits study protocol to FDA for CF102 Phase II trial for advanced liver cancer

The rising incidence of multi-drug resistant TB: an interview with Dr Myriam Haxaire-Theeuwes, Compound Development Team Leader, Janssen

Civitas reports positive results from CVT-301 Phase 2b trial for treatment of Parkinson's disease

Positive results from pivotal clinical trial of Trophos’ olesoxime in SMA patients to be presented at AAN 2014

Inflammation has ‘etiologic link’ with prostate cancer

Industry Focus eBook - Life Science Microscopy (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News